Science & academia

Two people holding hands

U.S. approves “milestone” Parkinson’s treatment for 2025 release

The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine hydrochloride to reduce ‘off’ episodes. These episodes are periods during the day and night when lepodova medication wears off and adverse motor-function symptoms become amplified. In trial, Onapgo significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment.

Illustration of the concept of nuclear fusion

China sets new fusion endurance record of over a thousand seconds

Fusion power is widely thought of as the holy grail of renewable, climate-friendly energy. Now, we are one step closer to realizing practical fusion power for the masses. The Experimental Advanced Superconducting Tokamak reactor in China’s Anhui Province has set a new record with a 1,066-second sustained fusion reaction. The new record builds on the previous record of 403 seconds set by EAST in 2023. The increase was made possible by a number of upgrades to the experimental system that have doubled the power output while keeping the reaction stable.

Woman with pink breast cancer ribbon

New therapy trial from Australian researchers nearly doubles breast cancer cure rates

A phase 3 clinical trial from Melbourne’s Peter MacCallum Cancer Center has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved the cure rate for patients with the most common kind of breast cancer. In the present phase 3 trial, 510 patients were randomized to receive chemotherapy with either intravenous nivolumab or placebo. In patients treated with nivolumab plus chemotherapy, rates were statistically significant, nearly double those who received placebo plus chemo: 24.5% versus 13.8%, respectively.

Depiction of intestines

“100% successful” cancer drug gets landmark U.S. FDA approval

Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the U.S. Food and Drug Administration granted it Breakthrough Therapy Designation status. The drug, a programmed death receptor-1-blocking antibody, completely eradicated rectal cancer tumors without the need for surgery, radiation treatment, or chemotherapy. “Everyone on the clinical trial is doing great,” Memorial Sloan Kettering Cancer Center gastrointestinal oncologist Andrea Cercek said. “So far, 42 people have completed treatment, and all of them have no evidence of disease. Side effects were quite mild and well tolerated.”

sidharth bhatia QstzxTWnXY unsplash scaled e

77% of universities have now pledged to divest from fossil fuels

115 U.K. universities have now pledged to exclude fossil fuel companies from their investment portfolios, following Birmingham City University, Glasgow School of Art, Royal Northern College of Music, and the University of Bradford all incorporating fossil fuel industry exclusions into their Ethical Investment Policies. The divested universities represent 77% of the U.K. Higher Education sector and more than $22 billion USD worth of endowments.

Molten iron ore

China develops new iron making method that boosts productivity by 3,600 times

The flash iron making method, as detailed by Professor Zhang Wenhai and his team in a paper published in the peer-reviewed journal Nonferrous Metals last month, can complete the iron making process in just three to six seconds, compared to the five to six hours required by traditional blast furnaces. According to Zhang and his colleagues, the new technology could improve energy use efficiency in China’s steel industry by over one-third. Additionally, by eliminating the need for coal entirely, it would help the steel industry achieve the goal of near-zero carbon dioxide emissions.

Model lungs

Doctors hail first breakthrough in asthma and COPD treatment in 50 years

A trial from King’s College London found offering patients a new injection was more effective than the current care of steroid tablets, and cuts the need for further treatment by 30%. The results, published in the Lancet Respiratory Medicine journal, could be transformative for millions of people with asthma and COPD around the world. Lead investigator Professor Mona Bafadhel said: “This could be a gamechanger for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in 50 years, despite causing 3.8 million deaths worldwide a year combined.”

Ovarian and Cervical Cancer Awareness. a Teal Ribbon

Cervical cancer deaths are plummeting among young U.S. women

Every year, thousands of American women die of cervical cancer. However, from 1992 to 2015, the number of deaths due to cervical cancer among U.S. women under the age of 25 fell steadily from each three-year period to the next, dropping roughly 75% altogether over that span. The sharp decline in cervical cancer deaths is likely due, at least in part, to the widespread introduction of the HPV vaccine in 2006.

MIT building

MIT will make tuition free for families earning less than $200,000 a year

Families making under $100,000 will not have to pay housing, dining or other fees, and they’ll have an allowance for books and other personal expenses. Families who make Families of students at the Massachusetts Institute of Technology (MIT) making under $100,000 will not have to pay housing, dining, or other fees, and they’ll have an allowance for books and other personal expenses. Families who make more than $200,000 a year can still receive need-based financial aid. Tuition for the 2024-2025 academic year at MIT is nearly $62,000. Housing, dining, and other fees can add up to another $24,000 annually, making it an enormous burden for families or forcing students to go into decades of debt.

Breakthrough genomic test identifies virtually any infection in one go

Researchers at University of California San Francisco (UCSF) have developed a single genomic test that can quickly detect virtually any kind of pathogen in a patient. This allows for much quicker diagnoses, enables targeted treatment to begin sooner, and could lower healthcare costs. Over the course of 7 years, researchers led by UCSF professor Charles Chiu tested 4,828 patients’ samples with its clinical mNGS method. The mNGS test accurately identified 86% of neurological infections.

Scroll to Top